a mid-cap pharma player, is witnessing strong momentum on the charts. However, its fundamentals still raise red flags for long-term investors. Positives: Stock has surged over 212.97% from its 52-week low, now only 7.56% away from its 52-week high. Technically strong: trading above 20, 50, and 200 DMA — signaling bullish trend continuation. Low PE stock (≤10), offering valuation comfort from a market perspective. Debt reduced from ₹1,790 Cr to ₹1,527 Cr – improved leverage profile. Institutional confidence rising: FII holding up from 6.54% → 6.81% DII holding up from 9.83% → 10.60% Overall institutional holding up from 16.37% → 17.41% Public holding dropped – often a sign of smart money accumulation. Negatives: Company continues to post losses, with a net loss of ₹45 Cr in the latest quarter. Negative ROE (-1.07%) for 3 straight years — reflects poor capital efficiency. Stock still trades at 5.3x its book value, despite weak profitability. Promoters increased pledged shares from 16.98% → 18.24% — a key risk signal. Bottom Line: Wockhardt is showing strong technical breakout signals, low PE, and improving institutional interest — making it attractive for short- to medium-term traders. However, long-term investors should stay cautious given continued losses, negative ROE, and rising promoter pledge. If you found this post helpful, do follow me for more such insights.

#StockInNews#WatchOutFor#FundamentalViews

265 likes·43 comments